ALKS logo

ALKS Alkermes plc

$40.52
$0.28
(0.69%)
Today
Closed $40.52
$0.00
(0.00%)
After Hours
55

Bullish Sentiment

How do you feel about ALKS?

Loading...
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
Zacks
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
Zacks
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.read more...
Benzinga
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.read more...
Benzinga
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the companys novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study...
Business Wire
Alkermes Appoints Anne Whitaker Member Of The Board
(RTTNews) - On Wednesday, Alkermes plc (ALKS) announced the appointment of a new independent director, Anne Whitaker, to the company's Board of Directors...
Nasdaq News: Markets
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the companys Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as...
Business Wire
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program
Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the...
Business Wire
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000...
Yahoo! Finance: News